Mécanismes de résistance aux thérapies ciblées (notice n° 659519)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01572cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121191923.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Guièze, Romain |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Mécanismes de résistance aux thérapies ciblées |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2020.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 54 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’arsenal thérapeutique de la leucémie lymphoïde chronique s’est considérablement enrichi avec le développement des inhibiteurs de la signalisation du récepteur B à l’antigène et d’un l’inhibiteur de BCL2 (pour B-cell lymphoma 2) : le vénétoclax. Des cas de résistances à chacune de ces molécules émergent et les mécanismes sous-jacents impliquant en partie des mutations de la cible thérapeutique sont en train d’être élucidés. Ils sont présentés dans cette revue. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Therapeutic landscape for patients with chronic lymphocytic leukemia is growing with the advent of BCR inhibitors and the BCL2 inhibitor venetoclax. Resistance cases are emerging and the underlying mechanisms such as mutations affecting the therapeutic target are being highlighted and compiled in the present review. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibrutinib |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | leucémie lymphoïde chronique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vénétoclax |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Résistance |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | resistance |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chronic lymphocytic leukemia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | venetoclax |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibrutinib |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 26 | N° Supp 3 | 2020-09-10 | p. 20-26 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2020-HS3-page-20?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2020-HS3-page-20?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux